Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Brief Summary
This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.
Condition or Disease
- Ketamine Adverse Reaction
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Recruiting |
| Study results: | No Results Available |
| Age: | 16 Years and older (Child, Adult, Older Adult) |
| Enrollment: | 140 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Mar 01, 2020 | |
|---|---|---|
| Primary Completion: | Dec 31, 2020 | |
| Completion Date: | Apr 30, 2021 | |
| Study First Posted: | Jul 28, 2020 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Jul 28, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
This is a double blinded study whereby both the surgeons and patients are blinded from the sedative agent used. Patients admitted to UKMMC requiring ERCP will randomized into 2 groups after evaluating the inclusion and exclusion criteria. Patients will be divided into two arms, Midazolam and Ketamine group respectively. Before the initiation of the the scope, patient would be given specified dose of sedation accordingly. All the parameters and outcome would be measured during and after the procedure.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 16 |
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
More Details
| NCT Number: | NCT04490031 |
|---|---|
| Other IDs: | Hukm |
| Study URL: | https://ClinicalTrials.gov/show/NCT04490031 |
Last updated: Jan 27, 2021